IO Biotech Announces Initiation of Phase II Trial of IO102-IO103 in Combination With KEYTRUDA^® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.